Strikingly, neuromuscular disease- but not skeletal dysplasia-causing mutations disrupt TRPV4-RhoA binding and the capacity of TRPV4 to inhibit RhoA activation (12, 28). Here, TRPV4 is linked to neuromuscular disease.